BIO just announced the Buzz of BIO, recognizing the most innovative companies at annual BIO Investor Forum, an investor conference focused on early and established private companies as well as emerging public companies. This year’s event will take place October 7-8 in San Francisco.
Legislators wrapped up their summer work in July before leaving town for the August recess, but not without some last minute drama over the Highway Trust Fund (HTF) and the border supplemental bill. Ultimately, lawmakers passed a funding extension for the Highway Trust Fund (HTF), staving off a financial crisis. Congress also moved forward on several tax items and continued to hold oversight hearings on the Affordable Care Act (ACA) implementation.Continue reading
A congenital heart defect brought Andrew Weaver close to death from end-stage biventricular heart failure. The SynCardia Heart kept him alive and helped build physical strength for his heart transplant.
Continue reading
Castle Biosciences Inc., a cancer-focused molecular diagnostics company, today announced the completion of an $11.8 million financing. The round was led by new investor HealthQuest Capital, with participation by Castle Biosciences’ current investors including Mountain Group Capital and Affiliates, Longfellow Venture Partners and others. In conjunction with this financing, Garheng Kong, M.D., Ph.D., Managing Partner of HealthQuest Capital, will join Castle Biosciences’ Board of Directors.Continue reading
W.J. “Jim” Lane, Mayor of Scottsdale, Arizona, has been selected as the recipient of the 2014 AZBio Public Service award by the Arizona BioIndustry Association.Continue reading
Novel clinical trial matching protocol enables greater access to genomic profiling and targeted clinical studies for cancer patients nationwide.Continue reading
After years of delving deep into DNA and researching ways in which metal damage may lead to cancer, a team of researchers is taking a step back to look at the surface where one answer may have been all along.Continue reading
High unmet need addressed with first new approved treatment in eighteen yearsContinue reading